113.50 0.00 (0.00%)
After hours: 4:34PM EDT
|Bid||113.41 x 1100|
|Ask||113.50 x 800|
|Day's range||112.36 - 115.20|
|52-week range||43.69 - 116.89|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||N/A|
|Earnings date||02 Nov 2020 - 06 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||120.47|
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan, president and chief executive officer, will present a company update at the following virtual investor conferences:
Per the DCLP5 study, Tandem Diabetes' (TNDM) insulin pump with Control-IQ technology suitable for use in children aged six to 13 years, which has been published in the NEJM.
Tandem announces New England Journal of Medicine publication of pediatric study showing increased time in range with Control-IQ technology.